Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.
FDA grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus vaccine candidate
September 7, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022